



US005480866A

United States Patent [19]

[11] Patent Number: **5,480,866**

Bonaventura et al.

[45] Date of Patent: * **Jan. 2, 1996**

[54] **HEMOPROTEINS FOR INHIBITION OF NITRIC OXIDE-MEDIATED HYPOTENSION AND SEPTIC SHOCK**

[75] Inventors: **Joseph Bonaventura**, Beaufort, N.C.; **Joseph DeAngelo**, Hamtramck, Mich.; **Robert G. Kilbourn**, Houston, Tex.

[73] Assignees: **Duke University; Apex Bioscience, Inc.**, both of Durham, N.C.; **Board of Regents, The University of Texas System**, Austin, Tex.

[*] Notice: The portion of the term of this patent subsequent to Mar. 22, 2011, has been disclaimed.

[21] Appl. No.: **184,637**

[22] Filed: **Jan. 18, 1994**

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 838,603, Feb. 19, 1992, Pat. No. 5,296,466.

[51] Int. Cl.⁶ **A61K 38/42**

[52] U.S. Cl. **514/6; 514/12; 514/21; 424/85.2; 530/385**

[58] Field of Search **514/6, 12, 21; 424/85.2; 530/385**

[56] References Cited

U.S. PATENT DOCUMENTS

4,061,736	12/1977	Morris et al.	424/177
4,584,130	4/1986	Bucci et al.	260/112
4,598,064	7/1986	Walder	514/6
4,751,068	6/1988	Bickar et al.	423/437
5,028,627	7/1991	Kilbourn et al.	514/565
5,082,642	1/1992	Bickar et al.	423/402
5,296,466	3/1994	Kilbourn et al.	514/6

FOREIGN PATENT DOCUMENTS

WO91/04024	4/1991	WIPO
WO91/84023	4/1991	WIPO
WO91/04023	4/1991	WIPO
WO93/00893	1/1993	WIPO

OTHER PUBLICATIONS

Bone, Roger C., *Annals of Internal Medicine*, vol. 115(6), pp. 457-469, 1991.

Glauser, M. P. et al., *The Lancet*, vol. 338, pp. 732-736, 1991.

Kilbourn, Robert G. et al., *Journ. of the National Cancer Institute*, vol. 84(11), pp. 827-831, 1992.

Natanson, Charles et al., *Annals of Internal Medicine*, vol. 120(9), pp. 771-783, 1994.

The Economist, "Panic in the Petri Dish," pp. 61-62, Jul. 23.

Cross, Alan S. et al., *Infection and Immunity*, vol. 61, No. 7, pp. 2741-2747, Jul. 1993.

Petros, Andy et al., *The Lancet*, vol. 338, pp. 1557-1558, 1991.

Kilbourn et al., "N^G-Methyl-L-arginine Inhibits Tumor Necrosis Factor-Induced Hypotension: Implications for the Involvement of Nitric Oxide," *Proc. Natl. Acad. Sci. USA*,

87:3629-3632, 1990.

Palmer et al., "Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor," *Nature*, 327:524-526, 1987.

Moncada et al., "Generation of Prostacycline and Endothelium-Derived Relaxing Factor from Endothelial Cells," *IN: Golles, G., Legran J. Y., and Nurden A. eds., Biology and Pathology of Platelets-Vessel Wall Interactions*, pp. 289-304, 1986.

Kilbourn et al., "Activated Macrophages Secrete a Soluble Factor that Inhibits Mitochondrial Respiration of Tumor Cells," *The Journal of Immunology*, 133(5):2577-2581, 1984.

Kilbourn & Belloni, "Endothelial Cell Production of Nitrogen Oxides in Response to Interferon γ in Combination with Tumor Necrosis Factor, Interleukin-1, or Endotoxin," *Journal of the National Cancer Institute*, 82:772-776, 1990.

Aisaka et al., "N^G-Methylarginine, an Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in Vivo?" *Biochemical and Biophysical Research Communications*, 160(2):881-886, 1989.

Vallance et al., "Effects of Endothelium-Derived Nitric Oxide on Peripheral Arteriolar Tone in Man," *Lancet*, 28:997-999, 1989.

Kilbourn et al., "Reversal of Endotoxin-Mediated Shock by N^G-Methyl-L-Arginine, an Inhibitor of Nitric Oxide Synthesis," *Biochemical and Biophysical Research Communications*, 172(3):1132-1138, 1990.

Gross et al., "Cytokine-activated Endothelial Cells Express and Isotype of Nitric Oxide Synthase Which is Tetrahydrobiopterin-Dependent. Calmodulin-Independent and Inhibited by Arginine Analogs with a Rank-Order of Potency Characteristic of Activated Macrophages," *Biochemical and Biophysical Research Communications*, 178(3):823-829, 1991.

Schmidt et al., "Insulin Secretion from Pancreatic B Cells Caused by L-Arginine-Derived Nitrogen Oxides," *Science*, 255:721-723, 1992.

Sakuma et al., "Identification of Arginine as a Precursor of Endothelium-Derived Relaxing Factor," *Proc. Natl. Acad. Sci. USA*, 85:8664-8667, 1988.

Stuehr & Marletta, "Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infections, Lymphokines, or

(List continued on next page.)

Primary Examiner—Michael G. Wityshyn

Assistant Examiner—C. Sayala

Attorney, Agent, or Firm—Arnold, White & Durkee

[57] ABSTRACT

The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock. Hemoproteins such as hemoglobin, myoglobin, hemalbumin and methemalbumin, for example, are useful when administered to a hypotensive patient.

14 Claims, 3 Drawing Sheets